NEW YORK, June 6, 2012 (GLOBE NEWSWIRE) -- Alliqua, Inc. (OTCBB:ALQA) ("Alliqua" or the "Company"), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced that Charles J. Wolff, D.P.M., F.A.C.F.A.S. has agreed to serve on the Alliqua Scientific Advisory Board ("SAB"). The SAB will provide scientific perspectives and strategic insight to enable Alliqua to leverage its hydrogel technology platform in the fields of wound care, transdermal drug delivery and other medical related categories.
Dr. Wolff is a graduate of the State University of New York at Albany and the New York College of Podiatric Medicine. He served his residency in the Northern Virginia Podiatric Residency Program of Georgetown University Hospital. He is presently the Director, Dept. of Podiatric Medicine and Surgery at Nyack Hospital in Nyack, NY, and staff attending at Good Samaritan Hospital in Suffern, NY, Ramapo Valley Surgical Center in Ramsey, NJ, Orange Regional Medical Center in Middletown, NY, and Meadowlands Hospital in Secaucus, NJ. Dr. Wolff is a fellow of the American College of Foot and Ankle Surgeons, and a member of the American Podiatric Medical Association and the New York State Podiatric Medical Society. He is Board Certified – American Board of Podiatric Surgery Reconstructive Rearfoot/Ankle Surgery and holds professional licenses in New York and New Jersey.
Dr. Wolff stated, "I am very pleased to have the opportunity to work with such a dynamic and innovative company like Alliqua. Having evaluated the Company's newly launched SilverSeal® silver based hydrogel wound dressing, I am very encouraged by its upside and the potential for further line extensions and improvements. I look forward to contributing to the development of SilverSeal® and other Alliqua products."
Richard Rosenblum, President, stated: "Dr. Wolff is a very well-respected practitioner in markets that our products serve. Having him join our Scientific Advisory Board will help us immensely in our commercialization and future development research efforts. He will be an excellent fit for our Board."
About Alliqua, Inc.
Alliqua, Inc. (OTCBB:ALQA) ("Alliqua") is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc. ("AquaMed"), Alliqua's subsidiary.
AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two manufacturers in the world for these gels. Alliqua's third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate™.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
For additional information, please visit www.alliqua.com
To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts
The Alliqua, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8820
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.